|1.||Nakagawara, Jyoji: 3 articles (01/2013 - 10/2010)|
|2.||Matsuda, Kazumi: 3 articles (05/2010 - 09/2002)|
|3.||Tamagami, Hiroshi: 3 articles (01/2005 - 09/2004)|
|4.||Morimoto, Kiyoshi: 3 articles (01/2005 - 09/2004)|
|5.||Suehiro, Eiichi: 2 articles (01/2013 - 10/2010)|
|6.||Iwanaga, Hideyuki: 2 articles (01/2013 - 10/2010)|
|7.||Suzuki, Michiyasu: 2 articles (01/2013 - 10/2010)|
|8.||Fujisawa, Hirosuke: 2 articles (01/2013 - 10/2010)|
|9.||Koizumi, Hiroyasu: 2 articles (01/2013 - 10/2010)|
|10.||Sasaki, Masayuki: 2 articles (09/2012 - 07/2011)|
|1.||Alzheimer Disease (Alzheimer's Disease)
10/01/1996 - "Reduced cortical distribution volume of iodine-123 iomazenil in Alzheimer's disease as a measure of loss of synapses."
09/01/1999 - "Early and delayed I-123 iomazenil SPECT images acquired 20 and 180 minutes after injection were compared with Tc-99m HMPAO SPECT studies acquired 15 to 20 minutes after injection in five patients with Alzheimer's disease. "
03/01/1997 - "This study was designed to elucidate a central type of benzodiazepine (Bz) receptor distribution in patients with Alzheimer's disease using SPECT with [123I]iomazenil (IMZ). "
09/01/1999 - "I-123 iomazenil SPECT in patients with Alzheimer's disease provided more sensitive information than Tc-99m HMPAO, allowing evaluation of brain perfusion and synaptic density."
09/01/1999 - "To compare brain perfusion and synaptic density in Alzheimer's disease assessed using I-123 iomazenil SPECT with brain perfusion assessed using Tc-99m HMPAO SPECT. "
|2.||Temporal Lobe Epilepsy
02/01/2013 - "To investigate involvement of extrafocal regions in mesial temporal lobe epilepsy (MTLE), we retrospectively explored abnormalities in distribution of iomazenil (IMZ) activity by identifying interhemispheric asymmetry on IMZ-SPECT images of patients with MTLE. "
02/01/2013 - "Altered extrafocal iomazenil activity in mesial temporal lobe epilepsy."
09/01/2002 - "Quantitative analysis of benzodiazepine receptor in temporal lobe epilepsy: [(125)I]iomazenil autoradiographic study of surgically resected specimens."
09/01/2004 - "Correct localization of epileptogenic focus with I-123 iomazenil cerebral benzodiazepine receptor imaging: a case report of temporal lobe epilepsy with discordant ictal cerebral blood flow SPECT."
09/01/2004 - "This study aimed at quantitatively evaluating hippocampal central-type benzodiazepine receptors (BZRs) in the kainate model of temporal lobe epilepsy (TLE) by in vitro autoradiography (ARG) using [(125)I] Iomazenil (IMZ) specific ligand for central-type BZRs. "
|3.||Partial Epilepsies (Epilepsy, Partial)
12/01/1997 - "FDG-PET seemed to localise the epileptogenic cortex more accurately than interictal iomazenil-SPECT in patients with complicated focal epilepsy."
06/01/2003 - "We have now applied single photon emission computed tomography (SPECT) with the benzodiazepine receptor inverse agonist [123I]iomazenil to examine cortical GABA(A) receptor density (GRD) before and 1 year after implantation of a VNS device in 10 subjects with drug-resistant partial epilepsy. "
02/01/2003 - "This review considers the clinical utility of iomazenil (IMZ) SPET and flumazenil (FMZ) PET for the precise localization of epileptogenic foci in partial epilepsy syndromes."
02/01/1994 - "[123I-iomazenil- and 99mTc-HMPAO in the diagnosis of focal epilepsies: a comparison of untreated and treated patients]."
10/01/1989 - "99mTc-HMPAO-SPECT and SPECT with the 123I-labelled benzodiazepine (Bz) receptor ligand Ro 16-0154 were performed in 10 patients suffering from partial epilepsy, without cerebral lesion in MRT or CT.2 h p.i. of Ro 16-0154 the distribution of activity correlated with the known distribution of Bz-receptors in the human brain. "
|4.||Schizophrenia (Dementia Praecox)
02/01/2011 - "In a double-blind, randomized, placebo-controlled study, clinically stable chronic schizophrenia patients (n=13) received iomazenil (3.7 μg administered intravenously over 10 min). "
02/01/2011 - "Iomazenil produced increases in psychotic symptoms and perceptual alterations in schizophrenia patients, but not in healthy controls. "
01/01/1997 - "Dynamic [123I]iomazenil SPECT was performed in 15 patients (14 patients with DSM-III-R schizophrenia and one with schizophreniform disorder) and 12 healthy subjects over a period of 2 hours. "
02/01/2011 - "The greater vulnerability of schizophrenia patients to the effects of iomazenil relative to controls provides further support for the GABA-deficit hypothesis of schizophrenia."
02/01/2011 - "Probing GABA receptor function in schizophrenia with iomazenil."
|5.||Mental Disorders (Mental Disorder)
10/01/1999 - "Ten akinetic catatonic patients, 10 psychiatric controls (similar age, sex, medication, and underlying psychiatric diagnosis but without catatonic syndrome), and 20 healthy controls were investigated with SPECT 2 hours after injection of (123) I Iomazenil. "
04/01/1999 - "Re: I-123 iomazenil SPECT in patients with mental disorders."
11/01/1997 - "I-123 iomazenil SPECT in patients with mental disorders."
11/01/1997 - "The purpose of this study is visual evaluation of the distribution of I-123 iomazenil in the brains of patients with various types of mental disorder and to examine whether chronic administration of a clinical dose of benzodiazepine (BZ) affects the binding of I-123 iomazenil to BZ receptors (BZR). "
|1.||GABA-A Receptors (GABA(A) Receptor)
|3.||Technetium Tc 99m Exametazime (Ceretec)
|5.||Oxyquinoline (8 Hydroxyquinoline)
|6.||Technetium (Technetium 99m)
|7.||Kainic Acid (Kainate)
|8.||Inosine Monophosphate (IMP)
|9.||GABA Receptors (GABA Receptor)